As previously reported, BofA analyst Jason Gerberry initiated coverage of Catalyst Pharmaceuticals with a Buy rating and $23 price target. The firm calls Catalyst “a unique aggregator of innovative therapies in the premium-multiple rare disease space” with a track record of “highly capital efficient” license and acquisition deals that have generated favorable return on investment. The firm believes the upcoming launch of muscular dystrophy drug Agamree will be successful given its competitive profile and views this launch as “the next phase of strategy validation,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CPRX:
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
- Catalyst Pharmaceuticals sees FY24 revenue $455M-$475M, consensus $463.19M
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals reports Q4 adjusted EPS 56c, consensus 26c
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
